02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
22:51 , Jan 24, 2019 |  BioCentury  |  Emerging Company Profile

Caelus' microbes for metabolic syndrome

Of the handful of companies aiming to harness the therapeutic potential of the microbiome, Caelus Health is the first to reach the clinic with a bacterial therapeutic for metabolic syndrome: an oral formulation of Eubacterium...
22:33 , May 24, 2018 |  BC Extra  |  Preclinical News

Striatal dopamine signaling regulates glucose metabolism

Researchers at Academic Medical Center (AMC) found that dopamine signaling is a key regulator of systemic glucose metabolism, which could guide exploration of new targets or interventions to increase insulin sensitivity in patients with chronic...
03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
01:30 , Jan 14, 2016 |  BC Extra  |  Financial News

Tmunity raises $10M for T cells

Tmunity Therapeutics Inc. (Philadelphia, Penn.) raised $10 million in a venture round from Penn Medicine and Lilly Asia Ventures to develop engineered T cell immunotherapies for cancer and infectious and autoimmune diseases. Tmunity said it...
07:00 , Aug 27, 2015 |  BC Innovations  |  Strategy

The Philadelphia story

Facing the headwinds of reduced funding from traditional sources, Thomas Jefferson University is restructuring to position itself as a local facilitator of innovation and industry partnership by slashing red tape and connecting to other institutions...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Activating mutations in the Ras-MAP kinase (MAPK) pathway to predict relapsed neuroblastoma response to MEK inhibitors

Biomarkers MEK Novartis AG Japan Tobacco Inc. Mekinist MAP kinase kinase 1 MAP2K1 MEK1 MAP kinase kinase 2 MAP2K2 MEK2 Exelixis Inc. Genentech Inc. Roche Array BioPharma Inc. Institut Curie Academic Medical Center University of...
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
07:00 , May 12, 2014 |  BioCentury  |  Emerging Company Profile

Inotrem: Sepsis companion

Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Cernostics, Academic Medical Center deal

Academic Medical Center (AMC) will provide Cernostics with access to a Barrett's esophagus patient registry, which the biotech will use to complete clinical validation studies of its TissueCypher: Barrett's . AMC has identified 5,000 patients...